John T. Mondick, Ph.D.

Group Leader, Sr Principal Scientist I

John has over 15 years of experience in the pharmaceutical industry and academia applying modeling and simulation to problems in clinical pharmacology. John’s interests include the application of modeling and simulation in pediatric pharmacology and the development of mechanistic models to optimize decision making in drug development.

Recent publications by this scientist

Latent process model of the 6-minute walk test in Duchenne muscular dystrophy

January 30, 2020

Lennie, J.L., Mondick, J.T. & Gastonguay, M.R. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy. J Pharmacokinet Pharmacodyn (2020).

View More

A latent variable disease progression model for Duchenne muscular dystrophy

October 9, 2018

Hajjar J. Poster presented at 2018 American Conference on Pharmacometrics (ACoP9). San Diego, CA. 9 Oct 2018. Abstract #T-011.

Download PDF

Population pharmacokinetic – pharmacodynamic analysis to characterize the effect of empagliflozin on renal glucose threshold in patients with type 1 diabetes mellitus

May 31, 2018

Mondick J, Riggs M, Kaspers S, Soleymanlou N, Marquard J, Nock V. J Clin Pharmacol. 58 (5): 640-649; May 2018

View More